Drug Database
AL

albumin (Zenalb)

✓ Approved

Kedrion · Cell-based Therapies · Cell-based Therapies

What is albumin?

albumin is a cell-based therapies developed by Kedrion. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesZenalb
CompanyKedrion
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Kedrion

Therapeutic Indications

albumin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved

Related Research Articles

PubMedIranian journal of pharmaceutical research : IJPR2026-09-20

Binding of Epimedium Flavonoids to Human Serum Albumin: Insights from Spectroscopic and Molecular Docking Studies.

Wang Na N, Wang Yuwei Y, Yang Yang Y, Dong Lele L et al.

Epimedin A (EA), epimedin B (EB), and epimedin C (EC), major bioactive flavonoids in Epimedium Herba, have diverse pharmacological activities; however, their interactions with human serum albumin (HSA) remain unclear. This study aimed to investigate the binding mechanisms of EA, EB, and EC to HSA. Multispectroscopic techniques, including UV-vis, fluorescence, and synchronous fluorescence spectroscopy, as well as molecular docking and dynamics simulations, were employed under simulated physiological conditions. Fluorescence spectra were recorded at 298, 303, and 310 K, and molecular docking was performed with HSA (PDB ID: 1BKE). All three flavonoids quenched the intrinsic fluorescence of HSA via static quenching, forming 1:1 complexes with binding constants greater than 104 L·mol-1 (EB > EA > EC at 298 K). Thermodynamic analysis indicated spontaneous binding driven by hydrogen bonds and van der Waals forces. Synchronous fluorescence showed no significant microenvironmental changes around Trp and Tyr residues. Molecular docking and dynamics simulations suggested ligand-dependent differences in the preferred binding regions of HSA. These findings provide preliminary in vitro evidence for the binding of epimedin flavonoids to HSA and may inform future pharmacokinetic investigations.

PMID 42763635
Read full article →
PubMedEsophagus : official journal of the Japan Esophageal Society2026-09-20

Long-term nutritional outcomes after esophagectomy following induction chemotherapy versus chemoradiotherapy for T4b esophageal cancer.

Sugimura Keijiro K, Tanaka Koji K, Sugase Takahito T, Momose Kota K et al.

The long-term impact of preoperative treatment on nutritional recovery after esophagectomy remains unclear. Although neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT) followed by surgery are established strategies for advanced esophageal cancer, their differential effects on postoperative weight loss have not been well characterized. This study aimed to compare long-term nutritional outcomes between esophagectomy after induction chemotherapy and after induction chemoradiotherapy in patients with T4b esophageal cancer. We retrospectively analyzed 86 patients with T4b esophageal cancer who underwent conversion surgery after induction treatment at six institutions between 2009 and 2021. Patients were categorized into a chemotherapy group (CT group, n = 51) and a chemoradiotherapy group (CRT group, n = 35). Longitudinal changes in body weight, lymphocyte counts, serum albumin levels, and prognostic nutritional index (PNI) were evaluated up to 24 months postoperatively. Postoperative weight loss was significantly greater in the CRT group than in the CT group, particularly at 9 and 12 months postoperatively (-13.4% vs. -9.6%, P = 0.011; -13.8% vs. -9.3%, P = 0.022). Weight loss persisted until 12 months after esophagectomy in the CRT group, whereas gradual recovery was observed after 6 months in the CT group. Lymphocyte counts were consistently lower in the CRT group from preoperation through 24 months postoperatively (all P < 0.05). Serum albumin levels did not differ significantly between groups. One year after surgery, deterioration in PNI was significantly greater in the CRT group (P < 0.001). Esophagectomy following induction chemoradiotherapy was associated with greater long-term weight loss and impaired nutritional recovery compared with surgery following chemotherapy alone. These findings highlight the need for intensified nutritional surveillance and intervention in patients treated with preoperative CRT.

PMID 42763385
Read full article →
PubMedViruses2026-09-20

Correction: Villalba et al. Development and Validation of Three Triplex Real-Time RT-PCR Assays for Typing African Horse Sickness Virus: Utility for Disease Control and Other Laboratory Applications. Viruses 2024, 16, 470.

Villalba Rubén R, Tena-Tomás Cristina C, Ruano María José MJ, Valero-Lorenzo Marta M et al.

In the original publication [...].

PMID 42763783
Read full article →
PubMedEuropean journal of nutrition2026-09-20

Exploring an energy-density adjustment to the Nutri-Score algorithm for general foods.

Amberntsson Anna A, Paulsen Mari Mohn MM, Bianchi Marta Angela MA, Birgisdottir Bryndis Eva BE et al.

The Nutri-Score categorizes foods by nutritional value per 100 g or 100 ml, which may lead to poor discriminatory ability for products with low energy density and large portion sizes, like ready-to-eat meals. We hypothesized that adapting the Nutri-Score algorithm to account for variation in energy density could better capture nutritional quality, particularly in lower energy-dense foods like ready meals, without substantially affecting other food scores. The aim of this study was to perform a proof‑of‑concept evaluation of adapting the Nutri-Score algorithm for general foods to different levels of energy density. This study utilized the Norwegian food databases Tradesolution and Unil (N = 25,813) to compare the energy-adjusted algorithm with the Nutri-Score 2023. The energy-adjusted Nutri-Score shifted food categorizations for 22% of products. Foods with low energy density, such as ready meals, showed increased scoring variation, indicating a more nuanced nutritional quality assessment, as intended. In these foods, we also saw a decline in favourable scores and an increase in unfavourable ones. However, high-energy-density food categories, like cakes and pastries, more often received more favourable scores. Also, the discriminatory ability between low-fat and full-fat products was reduced. While the energy-adjusted Nutri-Score improved scoring differentiation for certain low-energy-density foods, it showed unfavourable side-effects, indicating that overall, it is not superior to the Nutri-Score 2023. Nonetheless, adapting the algorithm to energy density offers potential for improved nutrient profiling methodologies in specific contexts. Further refinement of the weighting system could address observed weaknesses, optimizing this approach for broader application.

PMID 42763315
Read full article →
PubMedVascular health and risk management2026-09-20

Temporal Changes in Hospital-Captured 90-Day Care After Venous Thromboembolism: A 16-Year Electronic Health Record Cohort Study.

Wang Yonghui Y, Wang Yan Y, Zhang Xuemin X, Li Wei W et al.

Direct oral anticoagulants (DOACs) have simplified treatment for venous thromboembolism (VTE), but fewer mandatory monitoring visits may reduce opportunities for structured reassessment. We evaluated temporal changes in hospital-captured documentation of post-VTE care processes during the transition to DOAC-based treatment, including initial anticoagulation, clinical follow-up, laboratory monitoring, and selective imaging reassessment. We conducted a single-center retrospective electronic health record cohort study using routinely collected vascular surgery outpatient and inpatient records from Peking University People's Hospital between 2009 and 2024. Patients with VTE-related evidence and a definable hospital-captured index date were included. Treatment eras were prespecified as 2009-2014, 2015-2019, and 2020-2024. The study-defined documentation measure comprised therapeutic anticoagulation within 14 days and clinical follow-up, laboratory monitoring, and selective VTE-related ultrasound or imaging reassessment within 15-90 days. Among 5998 patients with a definable hospital-captured index VTE-related event, the median age was 64.0 years, and 55.3% were female. Documented anticoagulation within 14 days increased from 34.1% in 2009-2014 to 58.0% in 2020-2024. Within 15-90 days, clinical follow-up was documented in 1483 patients (24.7%), laboratory monitoring in 366 (6.1%), and VTE-related ultrasound or imaging reassessment in 578 (9.6%). All four prespecified domains were documented in 149 patients (2.5%) overall and in 3.2% during 2020-2024. In multivariable analysis, the 2020-2024 era, pulmonary embolism presentation, and upper-extremity or catheter-related VTE were associated with higher odds of four-domain documentation completion. In this 16-year electronic health record cohort, hospital-captured documentation of early anticoagulation increased, whereas documentation of 90-day follow-up processes remained infrequent; incomplete documentation or care delivered outside the hospital system may have contributed. These findings highlight opportunities to strengthen continuity and traceability of post-VTE management through timely clinical review and individualized decisions regarding treatment duration, safety monitoring, and selective imaging when clinically indicated.

PMID 42763763
Read full article →
PubMedNew microbes and new infections2026-09-20

Comparable severity of Plasmodium vivax and Plasmodium falciparum malaria in hospitalized patients in the Peruvian Amazon.

Bresciani Livia L, Guardiani Mariasilvia M, Rojas-Blasquez Manuel M, Ramirez Edgar E et al.

Plasmodium vivax malaria has long been considered less severe than P. falciparum infection. However, there is growing evidence that P. vivax can lead to severe and life-threatening disease, although its burden is likely to be underestimated, particularly in low-transmission settings.This study aimed to contextualize the application of World Health Organization (WHO) severe malaria criteria in a low-transmission setting by describing the clinical and parasitological profile of hospitalized malaria patients in the Peruvian Amazon. We conducted a retrospective hospital-based study at Hospital Regional de Loreto, Iquitos, Peru, from January 1, 2023, to October 30, 2025. The total hospital malaria caseload was determined from records assigned a laboratory-confirmed ICD-10 malaria diagnosis. The analytic cohort comprised hospitalized patients with microscopy-confirmed malaria who received intravenous artesunate because of severe malaria according to the WHO 2022 criteria, or inability to tolerate oral antimalarial treatment. During the study period, 519 laboratory-confirmed malaria diagnoses were recorded in the hospital; of these, 127 patients (24.5%) were hospitalized. Of these, 97 had P. vivax infection (76.4%), 27 had P. falciparum infection (21.3%), 2 had mixed P. vivax/P. falciparum infection (1.6%), and 1 had P. malariae infection (0.8%). Overall, 67 patients (52.8%) met criteria for severe malaria, which was observed in 51/97 patients with P. vivax (52.6%) and 14/27 patients with P. falciparum (51.9%), with no significant difference between species. Notably, patients with P. vivax malaria presented with severe manifestations including impaired consciousness, pulmonary oedema or acute respiratory distress syndrome, and shock. Laboratory differences between species were modest, although P. falciparum infections were associated with lower haemoglobin and glucose levels, while P. vivax was associated with more marked thrombocytopenia. Clinical outcomes were generally favourable, with one death to which malaria-related complications may have contributed. P. vivax contributed substantially to severe malaria in this low-transmission Amazonian setting and showed a severity profile similar to that of P. falciparum. The overlap observed between severe and non-severe presentations supports the contextual application of international severity criteria and continued recognition of the clinically important burden of P. vivax malaria.

PMID 42763549
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about albumin